Paris, October 8, 2009 – Cellectis S.A. (Alternext: ALCLS), the French genome engineering company, announced that the results of experiments conducted by Dr. Jean-Pierre de Villartay’s group from the French National Institute for Health and Medical Research (INSERM unit U768, headed by Professor Alain Fischer) at Necker Children’s Hospital, in collaboration with researchers at Cellectis have recently been published in the international, peer-reviewed journal Blood. The article reports the establishment of a new line of mice that enabled detailed investigation of the adaptive immune response (“Reduced immunoglobulin class switch recombination in the absence of Artemis”, Rivera-Munoz et al., Blood, Aug 19, 2009). This line also constitutes an important model for studying the meganuclease-based correction of genetic diseases thus leading Cellectis’ technology further in this therapeutic field.
